Sunday November 08 2009 | Biotechnology feed | All feeds
|
|
Sunday November 08 2009 | Biotechnology feed | All feeds
|
|
|
Immunotherapeutic targeting of P-glycoprotein Despite the appearance of a number of monoclonal antibodies in advanced stages of development, this therapeutic strategy has yet to live up to early promise. A recent area in which immunotherapy has been exploited is that of targeted immunotherapy (Click here for a full overview). This involves the targeting of toxins or isotopes to cancerous cells. Although the concept is simple a variety of hurdles have been encountered including poor penetration of solid tumors, antigen selection and selection of optimal toxins or isotopes. Antibody development has moved forward rapidly through the design of single-chain Fv fragments of larger antibodies and the truncated form of Pseudomonas exotoxin (PE38) has proved to be a useful component of immunotherapy. The selection of relevant antibodies is continuously evolving and one particularly exciting recent development has been reported by Israeli scientists. This group have cloned the Fv fragment of an antibody that selects for P-glycoprotein, a major drug resistance protein that is expressed by a variety of cancers and is responsible for many instances of drug resistance. This fragment was then fused to PE38 and the resulting molecule thus has considerable potential as a cancer tumor selective therapy Projects such as these are overviewed in full DiscoveryDossiers. DiscoveryDossiers ~ TherapeuticsAdvances ~ PharmaceuticalSolutions ~ LeadDiscovery ~ Purchase DiscoveryDossiersLeadDiscovery and BioPortfolio aims to provide reliable, insightful analysis on the biotechnology industry. However, this information is provided "as is" and no representations or warranties either express or implied of completeness, accuracy, or of any other nature are made with respect to this information. This information is neither an offer to sell nor a solicitation to buy the securities of any company. This information contains forward-looking statements, which involve risks and uncertainties which may not be listed. The biotechnology industry is an emerging industry and the securities of the companies mentioned in this report have a very high degree of risk and volatility. For this reason, this information is supplied on the condition that the reader will make his or her own determination as to its suitability for any purpose prior to any use of this information. The employees and officers of LeadDiscovery and BioPortfolio may hold positions in some or all of the stocks discussed in this report. This abstract has been produced by LeadDiscovery Ltd. Founded by life scientists for life scientists we aim to help industry identify cutting edge drug discovery options and academic/biotech institutions maximize the potential of their research. Abstracts strictly reflect the opinion of LeadDiscovery's editorial panel. While all reasonable efforts are made to ensure the accuracy of information provided LeadDiscovery and the publisher BioPortfolio, takes no responsibility for incorrect or misleading information. LeadDiscovery is designed for educational and drug development purposes only and is not intended or designed to offer medical advice or advice of any sort, and must not be used for such purpose. The information provided through LeadDiscovery and BioPortfolio should not be used for diagnosing or treating a health problem or a disease and no reliance should be placed on any information contained in this abstract or elsewhere on LeadDiscovery's and BioPortfolio's website. It is not intended to be a substitute for professional care. If you have or suspect you may have a health problem, you should consult your physician or other health care provider.
|
|
|
